TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05671081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcotic Analgesics
Description: patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
Study: NCT05810896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF at Home
Description: The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q\&A. Supplementary educations materials will be made available to participants.
Study: NCT06047405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Average Volume-Assured Pressure Support (AVAPS)
Description: A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)
Description: A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
Study: NCT05246254

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index scale
Description: There are clinically common scales for assessing weakness and delirium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index scale
Description: There are clinically common scales for assessing weakness and delirium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index scale
Description: There are clinically common scales for assessing weakness and delirium.
Study: NCT05463965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QM1114-DP
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT05146778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free anesthesia
Description: OFA group will be sedated using dexmedetomidine and lidocaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional opioid-based anesthesia
Description: Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
Study: NCT05925192

Intervention type: OTHER
Intervention: Observational study
Description: N/A - observational study
Study: NCT04268693

Intervention type: OTHER
Intervention: urine collection
Description: Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
Study: NCT04872088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthened SBCC
Description: Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preventive nutritional supplement
Description: Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~- \[6-17\]months old children diagnosed as non-wasted (MUAC\>=125mm)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family MUAC
Description: MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active screening by NASGs
Description: Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified followup of children with wasting referred to and enrolled in CMAM treatment
Description: NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention
Description: NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking demonstrations
Description: NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
Study: NCT06221176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being Brave
Description: Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
Study: NCT06204952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)
Description: In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
Study: NCT05313659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
Study: NCT05460403

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
Study: NCT00105599

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: End of life care coordination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FairCare System
Study: NCT05865132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 120mg/125mg po qd on day 1 to 21, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg/40mg po qd on day 1 to 28, every 28 days
Study: NCT06018727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 20 mg capsule will be administered orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: Yohimbine 20 mg capsule will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebos will be administered orally.
Study: NCT04715165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: USG-STAP with bupivacaine and dexmedetomidine
Description: Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IP bupivacaine and dexmedetomidine
Description: Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
Study: NCT06380673

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of cow's milk in decreasingly heated forms
Description: Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of cow's milk in decreasingly heated forms
Description: Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of heated cow's milk
Description: Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Healthy subjects undergo no intervention.
Study: NCT05591885

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study product group (Nutrilite Memory Builder)
Description: During study intervention, subjects are required to take the randomly assigned study product following the instructions.Take one tablet twice daily with meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: During study intervention, subjects are required to take the randomly assigned placebo following the instructions.Take one tablet twice daily with meals.
Study: NCT04720872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and vestibular rehabilitation treatment
Description: The experimental group received manual therapy and vestibular rehabilitation treatment.
Study: NCT06445933

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06313463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrellizumab + Capecitabine
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Capecitabine
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
Study: NCT05577416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Patients will undergo stereotactic biopsy by craniotomy or burr hole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Safusidenib Erbumine
Description: Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (maximal resection)
Description: Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Safusidenib Erbumine
Description: Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
Study: NCT04887467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Assigned Interventions:~* blood sampling~* blood collection~* systolic, diastolic, mean blood pressure and heart rate measure
Study: NCT04833374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
Study: NCT05619328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B combination tablet
Description: Once daily, with some liquid with or after a meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Once daily, with some liquid with or after a meal
Study: NCT06090006

Intervention type: OTHER
Group type: OTHER
Intervention: Screening package
Description: Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Psychosocial and mental health disorder screening
Description: HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
Study: NCT04726553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care treatments for Systemic Lupus Erythematosus
Study: NCT06454474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop tACS stimulation based on addiction-induced states
Description: We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states.
Study: NCT05494528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg once per day
Study: NCT05346796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan-Personal Health Record (SCP-PHR)
Description: The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
Study: NCT04782284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive swallowing rehabilitation
Description: The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing education
Description: The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
Study: NCT05185063

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care blood test
Description: The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
Study: NCT06090006

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Alcohol, tobacco and substance use screening
Description: World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet and physical activity screening
Description: HEEADSSS (Klein et al., 2014) and counselling and advice
Study: NCT05075278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: A survey will be completed by the participants at the conclusion of each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: A survey will be completed by the participants at the conclusion of each day.
Study: NCT05799846

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
Study: NCT06090006

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Underweight and overweight screening
Description: MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anemia
Description: Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (\<8g/dl) refer to health facility.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral health screening
Description: Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
Study: NCT05799846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMOTE Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
Study: NCT06141252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
Study: NCT04971499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Single-use vial containing 100 mg/4 mL of pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Single-use vial containing 100 mg/4 mL of pembrolizumab
Study: NCT05545475

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT05137236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.211
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.211
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.529
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.529
Description: Sterile liquid for injection
Study: NCT06088641

Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative BNP value
Description: preoperative BNP value

Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative BNP value
Description: preoperative BNP value
Study: NCT05862935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2
Description: 20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity: Phase 1
Description: 40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
Study: NCT05316558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Confident Coaching
Description: The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
Study: NCT04562974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-scanner
Description: Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.